The FT Vest Laddered Buffer ETF (BUFR) provides exposure to the S&P 500 with a unique options strategy that caps upside gains while offering 10% downside protection. This approach reduces volatility by 40% and maximum drawdown by 46% compared to the SPY ETF, though it has underperformed by 4.7% annually since inception. Despite a high expense ratio and no direct equity holdings, BUFR is rated a tactical Buy due to its strong risk-adjusted returns amid current macroeconomic uncertainty. Investors should consider these trade-offs when evaluating BUFR for portfolio diversification and risk management.
The FT Vest Laddered Buffer ETF (BUFR) offers a hedged equity strategy with downside protection, providing context for US stock market activity on Pluang. For readers following US stocks, here is Pluang's market snapshot as of Nov 11, 2026 00:02 WIB: out of 150 priced US stocks, 34 rose and 115 fell. Notable movers include NEM at USD 119.23 with a 1-day change of -4.74%, MRNA at USD 256.50 down 4.65%, and SOFI at USD 15.98 down 4.60%.
As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its sta...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...
Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...
Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...
